Introduction: In clinical trials comparing telavancin (TLV) with vancomycin for
INTRODUCTION
Telavancin is a semisynthetic lipoglycopeptide with broad-spectrum activity against gram-positive bacteria with different resistance phenotypes including methicillin-resistant S. aureus (MRSA), vancomycin-intermediate S.
aureus (VISA), heterogeneous VISA (hVISA) and VanB vancomycin-resistant enterococci (VRE) [1, 2] . Telavancin is approved for treatment of complicated skin and skin structure infections rates for monomicrobial infections caused by S. aureus including MRSA. However, patients with polymicrobial pneumonia had a better cure rate when they were treated with vancomycin (79.4%) compared to telavancin (66.2%), even though the difference did not reach statistical significance [4] . While it is possible that the reduced efficacy may be due to inadequacy of treatment based on susceptibility patterns of the isolated gram-negative pathogens, the reason for these discrepancies in cure rates is unknown.
There was a concern about reduced efficacy in patients with pre-existing renal impairment in comparison to vancomycin. In the study of 
Antimicrobial Agents
Telavancin powder was provided by its manufacturer (Theravance Biopharma Antibiotics, Inc., South San Francisco, CA).
Piperacillin, tazobactam and aztreonam were purchased commercially (Sigma Chemical Co.,
St. Louis, MO).

Media
Cation-adjusted Mueller-Hinton broth (MHB, Difco, Detroit MI) was used for PK/PD models and susceptibility testing. Polysorbate-80 was incorporated into the broth at 0.002% for any experiment involving telavancin to minimize drug loss due to binding to plastic materials [7, 8] 
Changes in Susceptibility
Development of resistance was evaluated by broth microdilution for any isolates observed at 96 h. If significant resistance development (defined as a Ctwofold increase in MIC from baseline) was detected at 96 h, samples from earlier time points were tested to detect for the earliest time point in MIC elevation.
Statistical Analysis
Changes in cfu/ml at 96 h were compared by one-way analysis of variance (ANOVA) with Tukey's post hoc test. A p value B0.05 was considered significant. All statistical analyses were performed using SPSS statistical software (release 22.0; SPSS, Inc., Chicago, IL).
RESULTS
Susceptibility Testing
The E. The bacterial regrowth observed poses a challenge in evaluating antagonistic activity between telavancin and either gram-negative antibiotic agent, if any exists. Therefore, in addition to P. aeruginosa, we evaluated two E. coli strains, which were presumed to be more susceptible to these agents based on MIC values.
The same pattern of significant regrowth was observed in PK/PD models with both E. coli strains when they were exposed to aztreonam without any significant changes in MIC. Both E. coli ATCC 25922 and clinical strain R1022 exhibited regrowth at 24 h in the presence of aztreonam at twice the MIC in time-kill assays (-0.6 cfu/ml ± 0.07 and ?0.74 cfu/ml ± 0.04 
